JPMorgan Chase & Co. Decreases Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

JPMorgan Chase & Co. cut its stake in REGENXBIO Inc. (NASDAQ:RGNX) by 17.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,477,311 shares of the biotechnology company’s stock after selling 535,165 shares during the quarter. JPMorgan Chase & Co. owned 5.00% of REGENXBIO worth $25,987,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Amalgamated Bank lifted its holdings in shares of REGENXBIO by 9.9% during the 2nd quarter. Amalgamated Bank now owns 13,613 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 1,227 shares during the period. FMR LLC increased its position in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares during the last quarter. Arizona State Retirement System grew its position in REGENXBIO by 20.6% during the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock valued at $137,000 after buying an additional 1,997 shares during the period. nVerses Capital LLC boosted its stake in shares of REGENXBIO by 183.3% during the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 2,200 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in shares of REGENXBIO by 19.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,375 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 3,015 shares in the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Stock Performance

Shares of NASDAQ:RGNX opened at $8.36 on Wednesday. The firm has a market cap of $414.20 million, a price-to-earnings ratio of -1.66 and a beta of 1.28. REGENXBIO Inc. has a fifty-two week low of $7.14 and a fifty-two week high of $28.80. The firm has a fifty day moving average price of $9.03 and a 200 day moving average price of $10.71.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on RGNX shares. Raymond James reiterated an “outperform” rating and set a $18.00 target price on shares of REGENXBIO in a research report on Thursday, October 10th. Chardan Capital reaffirmed a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a research report on Wednesday, November 20th. Royal Bank of Canada reissued an “outperform” rating and issued a $35.00 target price on shares of REGENXBIO in a report on Wednesday, December 11th. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $22.00 price target on shares of REGENXBIO in a research report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, REGENXBIO presently has an average rating of “Moderate Buy” and an average price target of $35.27.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.